We have recently reached a watershed in the research community’s consideration of the ethics of research. The way is now open for a more nuanced discussion than the one of the last decade in which attention to legal and quasi-legal procedures for handling misconduct dominated. The new discussion of ethical issues focused on trustworthiness takes us beyond consideration of conduct that is straightforwardly permitted, forbidden or required, to consideration of criteria for responsible behavior. This paper develops an overview of the (...) subject of trustworthiness among researchers. It illustrates and discusses various types of betrayal and defections in research conduct, and locates these in relation to many of the situations discussed elsewhere in this issue. (shrink)

The purpose of this article is to encourage and help inform active discussion of authorship policies among members of scientific societies. The article explains the history and rationale of the influential criteria for authorship developed by the International Committee of Medical Journal Editors, examines questions about those criteria that emerge from authorship policies adopted by several U.S. medical schools, and summarizes the arguments for replacing authorship with the contributorguarantor model. Finally, it concludes with a plea for scientific societies to play (...) a prominent role in the ongoing debates about authorship and the alternatives as part of their efforts to encourage ethical conduct among their members. Whether or not scientific societies develop authorship policies of their own, they should undertake vigorous educational efforts to keep their new members adequately informed about the importance of authorship practices in ethical scientific research and publication. (shrink)

Redundant publication in biomedical sciences is the presentation of the same information or data set more than once. Forms of redundant publication include “salami slicing”, in which similar text accompanies data presented in disaggregated fashion in different publications and “duplicate or multiple publication” in which identical information is presented with a virtually identical text. Estimates of prevalence of the phenomenon put it at 10 to 25% of published literature. Redundant publication can be considered unethical, or fraudulent, when the author(s) attempt (...) to conceal the existence of duplicate publication from editors and readers. Redundant publication in the area of clinical trials is potentially dangerous as it tends to overestimate the effects of interventions. The scientific community at large and governments should take urgent steps to safeguard the public from the possible effects of fraudulent multiple publications. (shrink)

The laissez-faire attitude towards dishonesty in research has simply created an environment for widespread escalation of the problem. Can we now believe anything we read? Why should we have confidence in an author because of his eminence? Should we automatically accept that clinical trials are always conducted with total integrity? Why have we been afraid to tackle this crisis head-on?